MyTomorrows, the Netherlands-headquartered startup that has built a system to aid medical professionals and patients access prescription drugs that are still in advancement, has elevated €10 million in further more funding. Foremost the spherical is EQT Ventures, and Octopus Ventures, with participation from existing backers Balderton Funds, and Sofinnova Associates. The Dutch startup would like to disrupt the way patients with unmet professional medical needs access advancement-stage solutions — prescription drugs that are still going through scientific trials and functioning their way by way of a lengthy regulatory approval process, or are currently authorized in one nation but not another. Launched in seventeen international locations, the myTomorrows system targets physicians and patients searching for information and facts and access to nascent prescription drugs although featuring drug advancement organizations a turn-important solution to operate worldwide early access applications. The plan is to make prescription drugs still in advancement accessible to patients suffering from existence threatening or debilitating health conditions, and obtain critical knowledge to bring all those prescription drugs completely to marketplace substantially sooner than may well otherwise occur. The myTomorrows databases has indexed 315,000 scientific trials and early access applications, combining knowledge from seventeen worldwide registries. Important to this is what the startup describes as a patient and health practitioner pleasant interface that aims to minimize information and facts asymmetry. It also would make the knowledge accessible via a general public API. I’m instructed that a new regulatory adjust in the U.S. (Scientific Trials Transparency Act) is putting stress on prescription drugs organizations to expand access and therefore driving adoption of myTomorrows. It’s been proposed that the Trump administration may well be additional liberal in respect to access to advancement-stage prescription drugs and health practitioner/patient selection too, but we’ll have wait around and see how that pans out. These issues are likely to be in the depth not the rhetoric. In the meantime, with the new funding, myTomorrows suggests it will make investments in engineering and headcount in buy to “unburden regulators, medical professionals and drug developers from the complex processes of supplying access to investigational prescription drugs for patients facing unmet professional medical needs”.
Supply backlink Share this:Click to share on Twitter (Opens in new window)Click to share on Facebook (Opens in new window)Click to share on Google+ (Opens in new window)
Related
MyTomorrows, the Netherlands-headquartered startup that has built a system to aid medical professionals and patients access prescription drugs that are still in advancement, has elevated €10 million in further more funding. Foremost the spherical is EQT Ventures, and Octopus Ventures, with participation from existing backers Balderton Funds, and Sofinnova Associates. The Dutch startup would like to disrupt the way patients with unmet professional medical needs access advancement-stage solutions — prescription drugs that are still going through scientific trials and functioning their way by way of a lengthy regulatory approval process, or are currently authorized in one nation but not another. Launched in seventeen international locations, the myTomorrows system targets physicians and patients searching for information and facts and access to nascent prescription drugs although featuring drug advancement organizations a turn-important solution to operate worldwide early access applications. The plan is to make prescription drugs still in advancement accessible to patients suffering from existence threatening or debilitating health conditions, and obtain critical knowledge to bring all those prescription drugs completely to marketplace substantially sooner than may well otherwise occur. The myTomorrows databases has indexed 315,000 scientific trials and early access applications, combining knowledge from seventeen worldwide registries. Important to this is what the startup describes as a patient and health practitioner pleasant interface that aims to minimize information and facts asymmetry. It also would make the knowledge accessible via a general public API. I’m instructed that a new regulatory adjust in the U.S. (Scientific Trials Transparency Act) is putting stress on prescription drugs organizations to expand access and therefore driving adoption of myTomorrows. It’s been proposed that the Trump administration may well be additional liberal in respect to access to advancement-stage prescription drugs and health practitioner/patient selection too, but we’ll have wait around and see how that pans out. These issues are likely to be in the depth not the rhetoric. In the meantime, with the new funding, myTomorrows suggests it will make investments in engineering and headcount in buy to “unburden regulators, medical professionals and drug developers from the complex processes of supplying access to investigational prescription drugs for patients facing unmet professional medical needs”.
MyTomorrows, the Netherlands-headquartered startup that has built a system to aid medical professionals and patients access prescription drugs that are still in advancement, has elevated €10 million in further more funding. Foremost the spherical is EQT Ventures, and Octopus Ventures, with participation from existing backers Balderton Funds, and Sofinnova Associates.
The Dutch startup would like to disrupt the way patients with unmet professional medical needs access advancement-stage solutions — prescription drugs that are still going through scientific trials and functioning their way by way of a lengthy regulatory approval process, or are currently authorized in one nation but not another.
Launched in seventeen international locations, the myTomorrows system targets physicians and patients searching for information and facts and access to nascent prescription drugs although featuring drug advancement organizations a turn-important solution to operate worldwide early access applications. The plan is to make prescription drugs still in advancement accessible to patients suffering from existence threatening or debilitating health conditions, and obtain critical knowledge to bring all those prescription drugs completely to marketplace substantially sooner than may well otherwise occur.
The myTomorrows databases has indexed 315,000 scientific trials and early access applications, combining knowledge from seventeen worldwide registries. Important to this is what the startup describes as a patient and health practitioner pleasant interface that aims to minimize information and facts asymmetry. It also would make the knowledge accessible via a general public API.
I’m instructed that a new regulatory adjust in the U.S. (Scientific Trials Transparency Act) is putting stress on prescription drugs organizations to expand access and therefore driving adoption of myTomorrows. It’s been proposed that the Trump administration may well be additional liberal in respect to access to advancement-stage prescription drugs and health practitioner/patient selection too, but we’ll have wait around and see how that pans out. These issues are likely to be in the depth not the rhetoric.
In the meantime, with the new funding, myTomorrows suggests it will make investments in engineering and headcount in buy to “unburden regulators, medical professionals and drug developers from the complex processes of supplying access to investigational prescription drugs for patients facing unmet professional medical needs”.